On­ly two-thirds of FDA-ap­proved biosim­i­lars have launched, re­port finds

As Pres­i­dent Don­ald Trump has sought to speed the de­vel­op­ment and ap­proval of new biosim­i­lar com­pe­ti­tion to ex­pen­sive bi­o­log­ics, on­ly 66% of FDA-ap­proved biosim­i­lars have …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER